NO20083059L - Pyrimidinderivater - Google Patents

Pyrimidinderivater

Info

Publication number
NO20083059L
NO20083059L NO20083059A NO20083059A NO20083059L NO 20083059 L NO20083059 L NO 20083059L NO 20083059 A NO20083059 A NO 20083059A NO 20083059 A NO20083059 A NO 20083059A NO 20083059 L NO20083059 L NO 20083059L
Authority
NO
Norway
Prior art keywords
relates
compounds
pyrimidine
ephb4
epha2
Prior art date
Application number
NO20083059A
Other languages
English (en)
Inventor
Jason Grant Kettle
Jon Read
Andrew Leach
Bernard Christope Barlaam
Richard Ducray
Christine Marie Paul La Brempt
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38229185&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20083059(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20083059L publication Critical patent/NO20083059L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Oppfinnelsen angår benzamidforbindelser med formel I eller et farmasøytisk akseptabelt salt derav, hvor R1, ring A, n, R3 og R4 er som definert i beskrivelsen. Foreliggende oppfinnelse angår også fremgangsmåter for fremstilling av slike forbindelser, farmasøytiske preparater inneholdende dem og anvendelse av dem ved fremstilling av et medikament for anvendelse som et antiproliferativt middel for forebygging eller behandling av tumorer eller andre proliferative tilstander som er sensitive for hemning av EphB4 og/eller EphA2 og/eller Src kinaser.
NO20083059A 2006-01-26 2008-07-09 Pyrimidinderivater NO20083059L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76238706P 2006-01-26 2006-01-26
PCT/GB2007/000251 WO2007085833A2 (en) 2006-01-26 2007-01-25 Pyrimidine derivatives

Publications (1)

Publication Number Publication Date
NO20083059L true NO20083059L (no) 2008-10-22

Family

ID=38229185

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20083059A NO20083059L (no) 2006-01-26 2008-07-09 Pyrimidinderivater

Country Status (16)

Country Link
US (1) US20110046108A1 (no)
EP (1) EP1981856A2 (no)
JP (1) JP2009524632A (no)
KR (1) KR20080089504A (no)
CN (1) CN101374818A (no)
AR (1) AR059218A1 (no)
AU (1) AU2007209126B2 (no)
BR (1) BRPI0707284A2 (no)
CA (1) CA2640375A1 (no)
IL (1) IL192610A0 (no)
NO (1) NO20083059L (no)
NZ (1) NZ569763A (no)
TW (1) TW200736232A (no)
UY (1) UY30107A1 (no)
WO (1) WO2007085833A2 (no)
ZA (1) ZA200806153B (no)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
CN1678321A (zh) 2002-07-29 2005-10-05 里格尔药品股份有限公司 用2,4－嘧啶二胺化合物治疗或者预防自体免疫性疾病的方法
US7122542B2 (en) 2003-07-30 2006-10-17 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
DK1856135T3 (da) 2005-01-19 2010-04-12 Rigel Pharmaceuticals Inc Prodrugs af 2,4-pyrimidindiamin-forbindelser og deres anvendelser
EP1984357B1 (en) 2006-02-17 2013-10-02 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds for treating or preventing autoimmune diseases
EP2089369B1 (en) 2006-10-19 2011-02-02 Rigel Pharmaceuticals, Inc. 2,4 -pyrimidinediamine derivatives as inhibitors of jak kinases for the treatment of autoimmune diseases
EP2222647B1 (en) 2006-10-23 2015-08-05 Cephalon, Inc. Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and c-met inhibitors
US20090036440A1 (en) * 2007-04-27 2009-02-05 Astrazeneca Ab Novel pyrimidine derivatives - 816
CN101796046A (zh) 2007-07-16 2010-08-04 阿斯利康(瑞典)有限公司 嘧啶衍生物934
WO2009010794A1 (en) * 2007-07-19 2009-01-22 Astrazeneca Ab 2,4-diamino-pyrimidine derivatives
EP2178870B1 (en) * 2007-08-17 2018-09-19 LG Chem, Ltd. Indole and indazole compounds as an inhibitor of cellular necrosis
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
MX2010012703A (es) 2008-05-21 2010-12-21 Ariad Pharma Inc Derivados fosforosos como inhibidores de cinasa.
US8450335B2 (en) * 2008-06-27 2013-05-28 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
US8338439B2 (en) * 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
US11351168B1 (en) 2008-06-27 2022-06-07 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
CN101659659B (zh) * 2008-08-29 2013-01-02 和记黄埔医药（上海）有限公司 嘧啶衍生物及其医药用途
WO2010072155A1 (zh) * 2008-12-26 2010-07-01 复旦大学 一种嘧啶类衍生物及其制备方法和用途
WO2010129053A2 (en) 2009-05-05 2010-11-11 Dana Farber Cancer Institute Egfr inhibitors and methods of treating disorders
AU2010295690B2 (en) 2009-09-16 2016-07-28 Celgene Avilomics Research, Inc. Protein kinase conjugates and inhibitors
WO2011082285A1 (en) 2009-12-30 2011-07-07 Avila Therapeutics, Inc. Ligand-directed covalent modification of protein
EP2536696A1 (en) 2010-02-18 2012-12-26 Concert Pharmaceuticals Inc. Pyrimidine derivatives
WO2011120025A1 (en) * 2010-03-26 2011-09-29 Glaxo Group Limited Indazolyl-pyrimidines as kinase inhibitors
AU2011254550B2 (en) 2010-05-21 2013-11-07 Noviga Research Ab Novel pyrimidine derivatives
EP2395001A1 (en) 2010-05-21 2011-12-14 Chemilia AB Novel pyrimidine derivatives
CN103096716B (zh) 2010-08-10 2016-03-02 西建阿维拉米斯研究公司 Btk抑制剂的苯磺酸盐
WO2012061303A1 (en) 2010-11-01 2012-05-10 Avila Therapeutics, Inc. Heteroaryl compounds and uses thereof
WO2012061299A1 (en) 2010-11-01 2012-05-10 Avila Therapeutics, Inc. Heterocyclic compounds and uses thereof
EP2637502B1 (en) 2010-11-10 2018-01-10 Celgene CAR LLC Mutant-selective egfr inhibitors and uses thereof
EP2502924A1 (en) 2011-03-24 2012-09-26 Chemilia AB Novel pyrimidine derivatives
JP5886411B2 (ja) 2011-03-24 2016-03-16 ノビガ・リサーチ・エービーＮｏｖｉｇａ Ｒｅｓｅａｒｃｈ ＡＢ 新規のピリミジン誘導体
AU2012250517B2 (en) 2011-05-04 2016-05-19 Takeda Pharmaceutical Company Limited Compounds for inhibiting cell proliferation in EGFR-driven cancers
WO2013054351A1 (en) * 2011-08-08 2013-04-18 Cadila Healthcare Limited Heterocyclic compounds
CA2853498A1 (en) 2011-10-28 2013-05-02 Celgene Avilomics Research, Inc. Methods of treating a bruton's tyrosine kinase disease or disorder
SG11201405691WA (en) 2012-03-15 2014-10-30 Celgene Avilomics Res Inc Solid forms of an epidermal growth factor receptor kinase inhibitor
CN104284584B (zh) 2012-03-15 2019-06-04 西建卡尔有限责任公司 表皮生长因子受体激酶抑制剂的盐
JP6469567B2 (ja) 2012-05-05 2019-02-13 アリアド・ファーマシューティカルズ・インコーポレイテッド Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物
EP2711364A1 (en) 2012-09-21 2014-03-26 Chemilia AB 4-(Indolyl or benzimidazolyl)amino-2-(2-(indol-3-yl)ethyl)aminopyrimidines useful for the treatment of cancer
EP2711365A1 (en) 2012-09-21 2014-03-26 Chemilia AB 4-Indazolylamino-2-(2-(indol-3-yl)ethyl)aminopyrimidines useful for the treatment of cancer
CA2890006C (en) * 2012-11-06 2021-11-23 Shanghai Fochon Pharmaceutical Co Ltd Alk kinase inhibitors
WO2014100748A1 (en) 2012-12-21 2014-06-26 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
MX2015009952A (es) 2013-02-08 2015-10-05 Celgene Avilomics Res Inc Inhibidores de cinasas reguladas por señales extracelulares (erk) y sus usos.
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
US9415049B2 (en) 2013-12-20 2016-08-16 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
EP3179858B1 (en) 2014-08-13 2019-05-15 Celgene Car Llc Forms and compositions of an erk inhibitor
LT3442947T (lt) * 2016-04-15 2023-09-11 Epizyme, Inc. Aminu pakeisti arilo arba heteroarilo junginiai, kaip ehmt1 ir ehmt2 inhibitoriai
CN118021814A (zh) 2017-04-21 2024-05-14 Epizyme股份有限公司 用ehmt2抑制剂进行的组合疗法
HUE063533T2 (hu) 2017-07-28 2024-01-28 Yuhan Corp Eljárás N-(5-((4-(4-((dimetilamino)metil)-3-fenil-1H-pirazol-1-il)pirimidin-2-il)amino) -4-metoxi-2-morfolinofenil)akrilamid elõállítására a megfelelõ amin és 3-halogén -propionil-klorid reagáltatásával
CN111234067B (zh) * 2018-11-29 2021-08-03 中国石油化工股份有限公司 用于烯烃聚合的固体催化剂组分和催化剂及其应用
CN113801108B (zh) * 2020-06-16 2024-02-27 中国药科大学 蛋白激酶抑制剂及其衍生物，制备方法、药物组合物和应用
WO2022063106A1 (en) * 2020-09-22 2022-03-31 Beigene, Ltd. Indoline compounds and derivatives as egfr inhibitors
US20240025902A1 (en) * 2020-09-30 2024-01-25 Beigene, Ltd. Bifunctional compounds for degradation of egfr and related methods of use
WO2024071415A1 (ja) * 2022-09-30 2024-04-04 日本ポリケム株式会社 化合物、金属錯体、オレフィン重合用触媒組成物、オレフィン重合用触媒、及び、オレフィン系重合体の製造方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002523497A (ja) * 1998-08-29 2002-07-30 アストラゼネカ・アクチエボラーグ ピリミジン化合物
CA2400447C (en) * 2000-02-17 2008-04-22 Amgen Inc. Kinase inhibitors
MXPA03005696A (es) * 2000-12-21 2003-10-06 Glaxo Group Ltd Pirimidinaminas como moduladores de angiogenesis.
US6939874B2 (en) * 2001-08-22 2005-09-06 Amgen Inc. Substituted pyrimidinyl derivatives and methods of use
WO2003030909A1 (en) * 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
AU2003231231A1 (en) * 2002-05-06 2003-11-11 Bayer Pharmaceuticals Corporation Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders
DE602004021472D1 (en) * 2003-02-20 2009-07-23 Smithkline Beecham Corp Pyrimiidinverbindungen
JP4607879B2 (ja) * 2003-08-15 2011-01-05 ノバルティス アーゲー 新生物疾患、炎症および免疫障害の処置に有用な２，４−ピリミジンジアミン
WO2006129100A1 (en) * 2005-06-03 2006-12-07 Glaxo Group Limited Novel compounds

Also Published As

Publication number Publication date
AU2007209126A1 (en) 2007-08-02
WO2007085833A3 (en) 2007-09-27
CN101374818A (zh) 2009-02-25
AR059218A1 (es) 2008-03-19
ZA200806153B (en) 2009-07-29
WO2007085833A2 (en) 2007-08-02
EP1981856A2 (en) 2008-10-22
US20110046108A1 (en) 2011-02-24
BRPI0707284A2 (pt) 2011-04-26
UY30107A1 (es) 2007-08-31
KR20080089504A (ko) 2008-10-06
JP2009524632A (ja) 2009-07-02
IL192610A0 (en) 2009-08-03
NZ569763A (en) 2012-06-29
CA2640375A1 (en) 2007-08-02
TW200736232A (en) 2007-10-01
AU2007209126B2 (en) 2012-01-19

Similar Documents

Publication Publication Date Title
NO20083059L (no) Pyrimidinderivater
SE0402735D0 (sv) Novel compounds
GB0612423D0 (en) Therapeutic agents
NO20081217L (no) Nye benzotiazolonderivater
NO20081582L (no) Benzamidforbindelser anvendbare som histon-deacetylaseinhibitorer
SG170101A1 (en) 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial.
NO20076197L (no) Nye 2-azetidinonderivater anvendbare i behandling av hyperlipidemiske tilstander
NO20090628L (no) Pyridizinon derivativater
NO20092737L (no) Substituerte pyrazolo-kinazolinderivater, fremgangsmate for deres fremstilling og deres anvendelse som kinase-inhibitorer
SG170069A1 (en) Quinoline derivatives
NO20071703L (no) Kinazolinderivater
NO20066081L (no) Kinazolinderivater som erbB-reseptortyrosinkinaser
NO20092476L (no) Antibakterielle polycykliske ureaforbindelser
NO20074592L (no) Acetylenyl-pyrazolo-pyrimidinderivater som mGluR2-antagonister
MX2008013836A (es) Derivados de 2-piridona para el tratamiento de enfermedades o condiciones en las cuales es benefica la inhibicion de la actividad de elastasa de neutrofilos.
TW200833675A (en) Nicotinamide derivatives
EA201391786A1 (ru) Галоген-алкил-1,3-оксазины в качестве ингибиторов bace1 и/или bace2
GEP20084452B (en) Sulfonamide derivatives for the treatment of diseases
MX2009010059A (es) Derivados de quinolina para el tratamiento de enfermedades inflamatorias.
TW200639156A (en) New compounds
NO20074258L (no) Pyridin-2-karboksamidderivater som MGLUR5 antagonister
NO20076137L (no) Nye 2-azetidinonderivater og deres anvendelse som kolestrolabsorpsjonsinhibitorer for behandling av hyperlipidemi
NO20076195L (no) Nye 2-azetidinonderivater for behandling av hyperlipidemiske sykdommer
MX2010009022A (es) Derivados 16 alfa, 17 alfa-acetal glucocorticoesteroideos y su uso.
SA519402103B1 (ar) 1,6-naphthyridine مشتقات 1، 6 نفثيرايدين CDK4/6 على شكل مثبط

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application